Canada markets close in 1 hour 20 minutes

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1791+0.0020 (+1.14%)
As of 02:24PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.1771
Open0.1501
BidN/A x N/A
AskN/A x N/A
Day's Range0.1501 - 0.1910
52 Week Range0.0600 - 0.9700
Volume53,900
Avg. Volume118,537
Market Cap56.918M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Small Pharma to Attend Upcoming Healthcare Conferences in January 2022

    LONDON, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at the 11th Annual LifeSci Partners Annual Corporate Access Event, and the H.C. Wainwright Bioconnect Conference, from January 5-7, 2022, and January 10-13, 2022, respectively. 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022)Sma

  • GlobeNewswire

    Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021

    LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces its participation in the H.C. Wainwright 2nd Annual Psychedelics Conference, which is being held virtually on Monday, December 6, 2021. A webcast presentation hosted by Peter Rands, Small Pharma’s Chief Executive Officer, will be available to view on demand beginning on December 6, 2021 at 7:00

  • GlobeNewswire

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the “Board”). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier ha